In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality.
Journal Article (Journal Article)
Kanie T, Mizuno A, Takaoka Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev. 2021;10:CD013650. 34693515.
Full Text
Duke Authors
Cited Authors
- Kelsey, MD; Newby, LK
Published Date
- March 2022
Published In
Volume / Issue
- 175 / 3
Start / End Page
- JC26 -
PubMed ID
- 35226528
Electronic International Standard Serial Number (EISSN)
- 1539-3704
Digital Object Identifier (DOI)
- 10.7326/J22-0003
Language
- eng
Conference Location
- United States